Uncovering Preoperative Characteristics Linked to Crohn’s Disease of the Pouch Post-IPAA
Patients who develop CDP after IPAA often face significantly lower QOL with a higher risk of septic complications and pouch failure.
Read MoreJun 25, 2024
Patients who develop CDP after IPAA often face significantly lower QOL with a higher risk of septic complications and pouch failure.
Read MoreJun 25, 2024
A study examining 20 years of data shows that race, ethnicity, and geography impact disease severity in patients with IBD.
Read MoreJun 25, 2024
The following is a summary of “Cost-Effectiveness and Impact on Health Care Utilization of...
Read MoreJun 3, 2024
The following is a summary of “Statins did not reduce the frequency of exacerbations in...
Read MoreNov 2, 2023
Lin Chang, MD, AGAF spoke with Physician’s Weekly about the guideline and the overall topic of pharmacological management of IBS-C.
Read MoreOct 17, 2023
Physician’s Weekly recently spoke with Linda Girgis, MD, FAAFP, about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Read MoreOct 13, 2023
Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, lead author of the phase 3 T3MPO-2 study—which assessed the efficacy of the NHE3 inhibitor tenapanor in treating patients with irritable bowel syndrome with constipation (IBS-C)—about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Read MoreSep 27, 2023
Physician’s Weekly recently spoke with Lin Chang, MD, AGAF, lead author of the 2022 AGA Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation (IBS-C).
Read MoreSep 19, 2023
Physician’s Weekly recently spoke with Brooks Cash, MD about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Read MoreAug 30, 2023
Physician’s Weekly recently spoke with Satish SC Rao, MD, PhD, FRCP, FACG, AGAF about NHE3 inhibitors and their unique method of action (MOA) in treating patients with IBS-C.
Read MoreAug 8, 2023
Physician’s Weekly spoke with a panel of experts in hepatology and oncology to discuss the role of two treatment guidelines in the management HCC.
Read MoreJul 25, 2023
Physician’s Weekly recently spoke with William D. Chey, MD, FACG, AGAF, FACP, RFF, the lead author...
Read MoreJul 25, 2023
Physician’s Weekly recently spoke with Brian E. Lacy, MD, PhD, a board-certified...
Read MoreJun 6, 2023
A novel trial underpins the differential impact that dietary fiber can have on IBS symptoms and...
Read MoreMay 17, 2023
Physician’s Weekly recently spoke with Gentry King, MD, a medical oncologist and published author...
Read MoreMay 16, 2023
Physician’s Weekly recently spoke with Robert Gish, MD, FAASLD, a self-identified hepatologist and...
Read MoreApr 18, 2023
We recently spoke with several experts in the management of advanced hepatocellular carcinoma...
Read MoreApr 18, 2023
Nadine Abi-Jaoudeh, MD, explains how tumor boards help ensure patients with advanced HCC receive individualized care, rather than based on “black and white” rules.
Read MoreMar 28, 2023
Along with the latest guidelines from the NCCN and ASCO, the American Association for the Study of...
Read MoreMar 28, 2023
“It is essential that all patients be evaluated by a multidisciplinary team prior to initiation of...
Read More